RNS Number : 9364Z
Byotrol PLC
24 September 2020
24 September 2020
Byotrol plc
PRELIMINARY RESULTS FOR THE YEAR ENDED 31 MARCH 2020
TRADING UPDATE
Byotrol plc (AIM: BYOT), the specialist infection prevention and control company is pleased to present its preliminary unaudited results for the year ended 31 March 2020 and provide a further update on current trading and the outlook for the current financial year.
Summary
The Directors were pleased with developments in the year, with good progress in financial performance and in all strategic initiatives.
The Directors are similarly pleased with performance to date and expect results for the year to 31 March 2021 to exceed current market expectations.
Financial highlights
Our results to the year were marginally above expectations across all key financial measures. Headlines are:
• Revenue at £6.07m (FY19: £5.66m)
• IP sales included in revenue £0.78m (FY19: £1.93m)
• Gross profit at £2.89m (FY19: £3.61m, including IP profit of £1.93m)
• Adjusted EBITDA at £0.26m (FY19: £1.08m)
• Pro forma cash £2.01m (FY19: £2.80m), net cash £1.42m (FY19: £2.55m)
• Cash resources supporting organic growth plans
Operational highlights
The Group also made steady progress operationally, including:
• Substantial increase in revenues from product sales compared to revenue from one-off transactions, increasing stability of the Group
• Acceleration of the earn-out relating to the acquisition of Medimark Scientific, resulting in an aggregate payment of £2.76m for a business that added over £3m in sales and c.£0.5m to EBITDA in the year, plus extensive sales and marketing expertise and leadership in human and animal health businesses
• New and/or upgraded agreements pre and post year end with first class collaborators in surface care and hand hygiene in EU and US
Current trading and outlook
Byotrol continues to perform well amidst the coronavirus pandemic, which the Directors believe will permanently increase global demand for antiviral and hygiene products and technologies. Trading remains strong across all key areas of the business and supply chains are now considerably easier than in March and April. Costs remain under control and certain costs, including those relating to exhibitions and travel, have been significantly reduced, at least in the short term.
Our forward order book now sits at £1.1m, reflecting a modest summer lull in purchasing activity and to some extent the evolution of the customer base. More sales are now being settled from stock, in which we have invested substantially since year end. We are also engaged in discussions with a small number of potential licensees with regard to IP licenses, although some of these are at an early stage.
As a result of the above, the Directors now expect Byotrol's profitability to exceed expectations set in recent trading updates.
Commenting on the results, John Langlands, Chairman of Byotrol plc, said:
We were pleased with Byotrol's progress in the year. The coronavirus pandemic has accelerated and magnified the business opportunities that we had already identified and now greatly increases the financial returns to be made. We remain confident that our technology-led positioning is the right approach in this market environment - including post coronavirus - and we remain confident in our financial outlook.
Enquiries:
Byotrol plc
David Traynor - Chief Executive Officer
Nic Hellyer - Chief Financial Officer 01925 742 000
finnCap
Geoff Nash/Kate Bannatyne - Corporate Finance 020 7220 0500
Richard Chambers - ECM
Flagstaff Strategic and Investor Communications
Tim Thompson/Andrea Seymour/Fergus Mellon 020 7129 1474
byotrol@flagstaffcomms.com
Presentation
A copy of the results presentation provided to investors and analysts will be available on Byotrol's website in due course.
Audited results
Byotrol also announces that its auditors have informed the Company that they may not have completed their internal clearance processes in time for the release of the final audited results on or before 30 September 2020 pursuant to AIM Rule 19. Whilst the Company is hopeful that the final results will be available by that date, pursuant to the guidance published by the London Stock Exchange in respect of the temporary measures for the publication of annual audited reports for AIM companies, Byotrol intends to utilise if needed the additional three month period to prepare and publish the audited results for the year. The Board confirms that there are not expected to be any material differences between the preliminary results in this announcement and the audited final results to be published in due course.
This announcement is released by Byotrol plc and, prior to publication, the information contained herein was deemed to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014. Such information is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person who arranged for the release of this announcement on behalf of Byotrol plc was Nic Hellyer, Chief Financial Officer.
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the Healthcare, Industrial, Food and Consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.
Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
Chairman's statement
Our strategy continues to be that of a technology-led company focusing on regulatory-approved specialist infection prevention and control technologies, commercialised by sales of products, licences and technology. This was another good year for the Group in delivering that strategy. Market conditions have obviously changed significantly since the coronavirus pandemic emerged and we believe that our markets have undergone a structural change. We remain confident that our positioning remains the right strategy for this new environment and that the pandemic will accelerate and increase the magnitude of changes that we had already been positioning for. Our team has responded very well to the crisis and we are already seeing the financial benefit in the current financial year.
Results and financing
Revenue for the year was £6.1m and adjusted EBITDA[1] £0.26m. Product sales increased from £3.5m in 2019 to £5.3m and the associated gross profit from £1.5m to just over £2.1m. We also recognised revenue and gross profit from IP agreements of £0.78m, lower than the prior year (which benefited from one large IP agreement with Solvay SA). These types of agreements will remain a key part of our commercial strategy, especially in markets that we are unable easily to access directly or where we can work with clear leaders in their field, and we reported two similar deals just after the year end, one in human hospital healthcare in the UK and another in the US. The recognition as upfront revenue of the stream of future fixed royalty payments which typically result from such deals can make it difficult for investors to appreciate the performance of the business in cashflow terms. I would therefore encourage shareholders to read the detail in the Financial Review section to gain a clearer understanding of our financial profile.
At the year-end we had cash resources[2] of £1.7m. Combined with positive cashflow since year end, we are well resourced to finance ongoing operations and steady growth.
Acceleration of earn-out and completion of acquisition of Medimark
We acquired the Medimark business in August 2018, with the total consideration being dependent on two years of earnout payments linked to stretch targets for EBITDA. The business traded profitably from the date of acquisition, but at the end of calendar year 2019, was thought likely to fall short of the original expectations. As a result, the vendors of Medimark agreed in January 2020 to accelerate the completion of the earn-out and accept a final payment of £0.45m (of which £0.29m was in cash and the remainder in shares), thus finalising the formal integration and enabling work on synergies across the Group to progress. The final agreement resulted in the total cost of the acquisition being approximately £2.8m.
We are very pleased with the performance of the Medimark team and see many potential synergies once the release of lockdown allows us fully to complete the integration process.
Impact of coronavirus
I am pleased to report that none of our staff have had to be treated for Covid-19 and have been able to work from home with minimal attendance at our offices. During the crisis the team has successfully dealt with internal and external lockdowns, extreme ebbs and flows of the supply chain and newer, larger and faster requirements from customers. I am pleased with how the team has responded to these challenges.
Group sales first started to increase in February 2020, principally from our agent in Japan. Sales then started to accelerate in Europe in March. The impact on FY20 sales was therefore small; however, sales have continued at a high level since the year end. It is clearly the case that the pandemic has boosted demand and interest in anti-microbial products, especially anti-virals. Business-wise this is all extremely favourable for Byotrol as that demand is now focused on sanitising products that are supported by comprehensive, detailed scientific and regulatory validation, set in law and increasingly policed by UK and EU regulators. The market is in a transition phase at the moment as the new regulations bite and we remain confident that our business will benefit as enforcement increases.
US operations
As reported in our last financial statements, the Directors concluded in 2019 that the risk/reward of Byotrol going alone into the US was less attractive than for other markets and that we should find a suitable partner. Having conducted a formal search process in conjunction with US advisers, we further concluded in January 2020 that we would make best returns by working with pragmatic, success-incentivised entrepreneurs rather than in, for example, a corporate alliance. This led to a new license agreement post year end over Byotrol24 surface sanitiser with Integrated Resources Inc., a newly-formed associate of our hand sanitiser licensee in the US.
Board and employees
The Byotrol team has performed extremely well this year, especially during the pandemic. We have managed to service our clients very effectively throughout, despite most of our own staff being locked down and our labs having to work on rota with skeleton staff only. I would like to thank them all for their efforts, commitment and enthusiasm this year. I would further like to thank our suppliers, especially our manufacturing partners, who have been putting in extraordinary efforts to satisfy demand for our products. We are pleased with the relationships we now have in place.
I would also like to announce a change at Board level, to be formalised at the next AGM. After 11 years with Byotrol, Dr Till Medinger will be stepping down as a non-executive director. We have enjoyed working with Till and recognise fully how important his advice and guidance has been through some turbulent times at Byotrol, thankfully now in the past. Our sincere thanks go to Till and our best wishes for his retirement.
Till will be replaced as non-executive director by Dr Trevor Francis, currently Chief Technology Officer. Trevor has been pivotal in all aspects of the Group's restructuring and whilst we respect his wish to retire from an executive role, we are delighted that he is staying with us at Board level. We know he will be a very active in his new position.
Trevor's management role in Byotrol will now pass to Dr Huw Evans, who has been with Byotrol for 5 years, prior to which he was a 28 year R&D executive at Unilever, including 20 years at director level. Huw has already been very successfully running our day-to-day technical operations for the last year, so the transition should be seamless.
AGM
The Company's AGM is expected to be held on a date to be confirmed in November 2020. In accordance with current restrictions on gatherings of more than 6 people, it is expected that the AGM will be held fully or partly virtually (with attendance and voting occurring electronically), without any requirement for a physical location for the meeting; however, a decision on this will be made in due course depending on whether requirements or legislation changes. The Company values the participation of smaller and retail shareholders and In any event due consideration will be given to enabling participation at the AGM, possibly by way of a prior Q&A facility.
In addition to the normal business of the AGM, the Board also intends to propose resolutions to reduce the share premium account and other reserves in order to create a positive retained earnings balance and hence distributable reserves which would enable the Company to pay a dividend if and when deemed appropriate. In addition, the Board is also considering taking the opportunity to consolidate the share capital in order that the Company has fewer shares in issue but each share having a higher nominal value.
Further announcements and communication regarding the AGM and these other matters will be made in due course.
Prospects
We remain steadfast in our belief that the winners in our industry will be those that are science-led, validated by regulators and fully aware of the complexities and risk/rewards of using biocides. Towards the end of calendar 2019, we were starting to see the benefits of that approach and were trading profitably in product sales with less reliance on one-off agreements.
Coronavirus has accelerated and magnified the changes that we were already seeing and we believe greatly increases the financial returns to be made. However, we also see the new environment as increasing the good that the team can do for society and the environment, and as a result we will continue to invest and research into new and better ways to control and prevent infections. These things together are extraordinarily motivating for the team and I believe will benefit all stakeholders in due course.
The new financial year has started very well and should deliver excellent results, marking a significant step in Byotrol's history as it moves towards being a sustainably profitable business. We currently see many opportunities and are constantly reviewing where we should best focus our efforts to maximise returns in the long-term.
The Board remains confident in our positioning and very optimistic for Byotrol's prospects.
John Langlands
Chairman
Chief Executive's statement
The year in overview
We are pleased with the improvement in quality and reliability of income this year, with continued increase in trading income (product sales and multi-year royalty and commission) compared to our historic performance and a decrease in reliance on one-off income. This was a key target for the team this year and, with Medimark fully part of the Group, the portents are good for continuing this trend, although monetisation of technical development will remain a key part of our commercial model.
The Board was already pleased with progress of the Group prior to the coronavirus outbreak, with all major targets being met. The impact of the pandemic has accelerated and magnified the trends in our industry, greatly to our benefit, although the financial impact of this will only be seen in FY21. We remain confident that our strategy is the right one for the new world too.
The impact of coronavirus
Shareholders will be aware that our strategy is to take advantage of regulatory change in our markets in a similar way to many pharmaceutical and pesticide firms which went through similar industry change - by taking a very scientific approach to our industry and developing and commercialising unique, high-performance and trusted technologies that are approved (and then protected) under national and supra-national regulatory rules. We then seek to monetise those technologies by way of IP sale and alliances, license agreements and finished product sale, in both business and consumer markets.
We were already seeing the benefits of this strategy in late 2019 as weaker competition started to fade away and as larger customers became more rigorous on demanding data and regulatory support for product claims. We viewed this process as a slow-moving supply shock to the industry, favouring high quality science-led technologies. By early March 2020 it was becoming clear that coronavirus was an exceptionally dangerous virus with no current cure and would need multiple and extraordinary actions to prevent its spread and to deal with the consequences, many of which remain in place. This produced a large and immediate positive demand shock for our industry, especially for those companies with high performance anti-viral capability such as us. These two forces have together created a highly favourable business climate for Byotrol, which we have since been seeking to benefit from, in a calm, professional and ethical way.
Our team's initial focus was on satisfying demand from ultimate end users in emergency services and critical health services, then for all existing customers and then from new enquiries. In parallel with this we have been working on positioning for a post-coronavirus world, with less hype, but with more understanding of the importance of high-quality infection control and prevention products amongst individuals, governments and corporations worldwide.
Markets
Professional
Full year revenues increased to £5.19m from £2.71m and gross profit to £2.47m from £1.09m, including the first full year contribution from Medimark. Income from IP licensing and sales for the year was £0.78m. Gross margin for product sales in Professional across the enlarged Group declined marginally to 38%, though this improves substantially once 100% gross margin IP income is factored in.
With the full integration of Medimark staff and customers into the Group, we are now seeing encouraging growth in everyday healthcare-related areas for both animals (veterinary sector) and humans (community health), plus continued sales into facilities management, travel and leisure and into a limited number of long-standing food manufacturing customers.
Our product mix for finished goods remains focused on surface care products, representing 29% of sales in the year, but our alcohol-free hand sanitisers continue to grow rapidly, even more so since the pandemic started. We are considering range extensions in this area as we clearly have a valuable base proposition, good long term customers and an increasingly recognised brand 'Invirtu'.
For markets where we are unable to compete effectively with our own resources, we have continued to enter into licensing agreements with high-quality partners, especially those able to manufacture products themselves. We completed two such agreements prior to year-end, one with Tristel plc, fellow infection control and prevention specialists, with an exceptionally strong business based on chlorine dioxide chemistries, and one with Advanced Hygienics LLP in the US. The Tristel agreement relates to three specific surface care technologies targeted for use in hospitals in UK and Ireland, two of which will be dispensed from Tristel's proprietary 'Cache' system of innovative packaging solutions. The agreement has a duration of 10 years, is exclusive in hospitals in the UK and Ireland and non-exclusive elsewhere and will pay to Byotrol a combination of product supply payments, royalties and fees, based on success but with meaningful minimum guarantee payments to Byotrol each year.
The agreement with Advanced Hygienics represented an extension of an existing alcohol-free hand sanitising agreement and introduced multi-year minimum guaranteed royalties. We understand this business has been performing well during the pandemic. All existing alliances - including the well-publicised agreement with Solvay - ran to expectations in the year under review and we remain hopeful that they will bear financial fruit for the Group during and post the pandemic.
Consumer
We have now combined our consumer and petcare activities into one team. Although the bulk of our resources this year were focussed on our Professional business, we continued to make progress in some new consumer initiatives, including the following:
• new petcare customer, Manna Pro UK, launched its first Byotrol surface care product, under leading stain and odour brand "Simple Solution" in the UK via retailers Pets at Home and Amazon
• established European partner Beaphar has introduced Byotrol surface care products into its UK range, completing the roll out plan for distribution throughout Beaphar's network
• Pets at Home, completed a range review on the small animal category, launching several new Byotrol products and approved the use of Invirtu hand sanitiser in stores and at head office for colleagues and the general public; and
• Byotrol entered the consumer floorcare category via two new partnerships with heritage British brand, Swan and RK Wholesale, under the licensed Tower brand. Byotrol formulations are used in conjunction with floorcare appliances to clean and sanitise carpets and floorcoverings with "better than leading brand" performance; further product launches are planned for 2020/21
Finally, Byotrol's alcohol-free hand sanitiser sales under Boots' own-brand were starting to increase significantly towards year end. This trend continued post year end and we expect to report substantial sales of this product in the new financial year.
Revenues from product sales increased to £0.88m from £0.79m in the previous year and gross profit also increased, to £0.42m from £0.36m as a result of an improved product mix. We did not generate any income from IP transactions or licenses in the consumer segment in the year under review.
Supply chain and regulatory environment
Prior to the coronavirus pandemic we had been working hard to improve our supply chain. We are pleased to report that this initiative has substantially reduced non-conformances and returns. As the pandemic took hold, the team has dealt with many extraneous shocks to the new processes and substantially increased despatch rates
The research and development team has also been working throughout the crisis, formally supporting coronavirus-specific product claims on top of their normal day-to-day responsibilities. We continue to research into natural-based anti-viral chemistries, of which extracts from seaweed is our leading contender.
The coronavirus pandemic has encouraged some new suppliers into our market, keen to make a quick return. We have seen several misleading product claim and commentaries, but we believe that increasing enforcement of regulation and product claims in our markets will lead to their removal in due course.
We continue to follow developments on Brexit very carefully and have taken all necessary steps to ensure there is minimal impact on our business, even in the event of no trade agreement between the UK and EU. With around 10% of our enlarged business comprising exports to the EU, newly imposed tariffs would probably have a modest impact on our performance in the short term.
Outlook
Post year end we completed two further IP agreements, with Integrated Resources LLP (who took out a license over Byotrol24 in the US) and SC Johnson Professional Limited in alcohol-free hand sanitisers, sold under the SC Johnson Professional brand. The latter is a multi-year license agreement focused on the UK and Irish health services, superseding a pre-existing, short-dated supply and manufacturing agreement. We expect the strength of our technology to lead to further such deals in the future.
For product sales the outlook for Byotrol is also highly positive. Sales have of course increased as a result of the coronavirus pandemic and will probably ease somewhat eventually, but it is clear to us that:
• business and consumers will now take more proactive responsibility for protecting individuals against infection risk, leading to sustained demand for anti-microbials, especially anti-virals
• there is now a further acceptance of the role of regulators as opinion leaders on safe and efficacious anti-microbial chemistries, for which we are well-positioned; and
• competitors with weaker performance chemistries continue to withdraw from our market in UK and Europe as regulations take hold, increasing opportunities for us, either organically or by selective acquisition
Byotrol has been positioning for such trends for many years and expects them to favour technologies like ours, presenting exceptional growth opportunities for the Group at home and abroad.
David Traynor
Chief Executive Officer
Financial Review
Our results for the year show further success in monetising the Group's proprietary technologies as well as continuing progress in the product side of the business. The latter has benefited from a full year contribution from the Medimark business (acquired in August 2018) which diversified the Group's product range and brought a significant new customer base. Furthermore, following the renegotiation and acceleration in January of earnout payments potentially due in respect of that acquisition, the various businesses within the Group are now fully aligned and well-placed to benefit from cross-product selling opportunities as well as cost savings and other efficiencies in the supply chain. Clearly the Group has experienced significantly increase sales volumes since the outbreak of coronavirus (which was declared as a pandemic by the WHO on March 11); however, this increase did not materially affect the results for FY20.
Income Statement
Revenue
As part of the continued evolution of the Group we have simplified our reporting segments into two: Professional (Byotrol and Medimark products for use within businesses and institutions) and Consumer (Byotrol and Medimark products for individual consumers, including their pets):
Professional
Revenues increased to £5.19m from £2.71m, with gross profit increasing from £1.09m to £2.47m. Included in the FY20 figure is £0.78m of royalty and licensing income (2019: nil). Excluding this, revenue from this division increased by around 63%, reflecting both a full year contribution from Medimark (against a seven month contribution in the comparable period) as well as increased demand for our surface care products and hand sanitisers.
Consumer
Total revenue in the Consumer segment decreased to £0.88m from £2.95m; however, included in the FY19 figure is £2.16m of income from royalties, licensing and the sale of intellectual property - revenue from product sales in this division increased by around 11%, due to both new customers as well as increasing sales from existing customers.
Finance income
In addition to the above, notional finance income arose from the imputed cost of funds on long-term contracts (£33,000 in 2020; 2019: £20,000). This has been added back to adjusted EBITDA in the calculation set out in Note 8.
Cost of sales
Cost of sales of £3.18m (2019: £2.06m) represents the direct manufacturing costs of products and the cost of logistics (warehousing, transport etc). Given the mix of Byotrol's activities, gross margin across the sales mix is not a particularly meaningful measure of performance and is better considered on a segmental by product basis. In the Professional segment (excluding royalties, IP etc.), the gross margin declined marginally to 38%. For the Consumer business (again excluding royalties, IP etc.) the gross margin increased to 48% (2019: 45%). In the absence of other factors, we would expect gross margins across the business to benefit in due course from the greater scale and pricing power of the Group as enlarged by the acquisition of Medimark, as well as an increasing rationalisation of the product portfolio; however, with the constraints on the supply chain resulting from the impact of the coronavirus pandemic we have seen some pressure on gross margins over the course of FY21 to date, albeit we expect this effect to be short-term.
Overhead expenses and research and development
The acquisition of the Medimark business brought some 13 additional staff and management and FY20 shows the full year effect of this; however, with certain cost savings and efficiencies costs have been broadly maintained at around £2.78m (2019: £2.73m). Of this, some £1.59m (2019: £1.53m) related to staff costs. Given the improving financial performance of the business, we intend to target investment in our staff and the infrastructure of the business to support high quality products, a high level of customer service and to provide a strong, scalable platform for continued organic growth.
Expensed research and development costs remained broadly constant at £0.41m (2019: £0.44m). The Group continues to invest in the research and development of further anti-microbial products and has 9 employees in its research and development department. Furthermore, the Group continues to collaborate with respected research institutions (typically universities) to supplement the internal resource. This continued investment is essential for the maintenance of the Group's market position and for future growth.
Exceptional items
Exceptional items of £0.38m in 2020 comprise principally the gain relating to the adjustment of liabilities arising from the renegotiation of the potential earnout payment in respect of the acquisition of Medimark, which renegotiation resulted in a payment of approximately £290,000 in cash and the issue of 9.4m new Ordinary shares in full and final settlement of the potential amounts outstanding under the terms of the sale and purchase agreement. This reduced the aggregate payment made in respect of the acquisition to approximately £2.76m and a gain of £0.44m arose based on the elimination of the liability recognised at the last reporting date after taking into account the cost of unwinding the discount to that date.
Finance income and expense
Finance income arises both from interest receivable on interest-bearing deposits as well as notional interest arising on contracts with a "Significant Financing Component" as defined by IFRS 15. The increase in the latter from £20,000 to £33,000 relates principally to a full year of finance income accruing on the Solvay contract, the revenue for which was recognised in FY19.
Finance expense of £0.13m (2019: £0.08m) comprises mainly the non-cash cost of amounts arising from the discounting of liabilities related to contingent consideration relating to the acquisition of Medimark to their expected value at the relevant reporting date. The balance comprises cash interest on the Group's factoring facility, bank charges and an element of lease expenses now recognised as interest under IFRS 16. As noted above, the renegotiation and acceleration of potential earnout payments due in respect of the Medimark acquisition has eliminated the liabilities recognised and hence no further finance expense will accrue. In addition, given the improving cash flow of the Group, the usage of the factoring facility has been considerably reduced in FY21, and we would expect limited, if any, further use assuming trading conditions remain favourable.
Implementation of IFRS 16
The Group adopted IFRS 16 Leases for the financial year ending 31 March 2020 and chose to use the modified retrospective approach to adoption which means there are no restatements to the prior year figures. IFRS 16 introduces a single lessee accounting model, whereby the Group recognised lease liabilities and "right of use" assets at 1 April 2019 for leases previously classified as operating leases. Within the income statement rental expense is replaced by depreciation and interest expense.
The Group has very few operating leases which fall under IFRS 16 (one property lease and a small number of vehicle leases). The adoption of IFRS 16 has resulted in the recognition of aggregate right of use assets of £69,000 with corresponding liabilities of £70,000 as at 31 March 2020. The effect on net profit is negligible; however. in order to allow users of the accounts to see how the impact of IFRS 16 has affected adjusted EBITDA, we present a reconciliation below:
Adjusted EBITDA
Adjusted EBITDA
Year to 31 March 2020
Year to 31 March 2019
£'000
£'000
Consistent with FY 2019 presentation and accounting policy
216
1,079
Changes due to IFRS 16
42
-
_______
_______
Consistent with FY 2020 presentation and accounting policy
258
1,079
Profitability
Adjusted EBITDA decreased by 76% in the year to £0.26m (2019: £1.08m), this fall being due largely to the £1.93m income from IP sales recognised in FY19 compared to similar income of £0.78m in FY20. Similarly the Group made a pre-tax loss of £43,000 (2019: £0.34m profit). After a tax credit of £0.38m (2019: £11,000) this resulted in statutory EPS of 0.08p (2019: 0.08p) and 0.06p on an adjusted basis (2019: 0.16p).
Taxation
Taxable profits arising in the year to 31 March 2020 were wholly off-settable against tax losses brought forward and accordingly no taxation was payable. Significant tax losses remain available to the Group; historically the Group has not recognised any deferred tax asset on these losses due to the unpredictability of the timing of future profit streams. Given the significant improvement in the trading position of the Group, the Board reassessed the appropriateness of recognising such an asset on the basis of forecast profits against which the losses can be offset and now consider it appropriate to recognise losses incurred to date as a deferred tax asset. Accordingly a deferred tax asset of £0.43m has been recognised (2019: £nil)
A tax credit also arises from the amortisation of a deferred tax liability relating to the intangible assets acquired as a result of the acquisition of Medimark.
Statement of Financial Position
Goodwill and other intangible assets
Goodwill, customer relationships and brands
The intangible assets acquired as part of the Medimark Acquisition comprised principally customer relationships, various brand, as well as other IP relating to the capitalised value of efficacy testing and other relevant licensing activities. Net of accumulated amortisation for the year, the net book value of the customer relationships and brands acquired was approximately £2.04m at the year end (2019: £2.28m). Goodwill arising on acquisition was £0.50m, which remains unchanged.
Development costs
Development costs represent the capitalised value of work undertaken (either internally or externally by appropriate consultants) to develop and protect patents, know-how and other similar assets when they pass the criteria for capitalisation under the Group accounting policy. The amortised balance at 31 March 2020 was £0.94m (2019: £0.85m) after capitalised expenditure of £0.25m and amortisation and impairment of £0.16m.
Patents and licenses
The Group continues to protect its IP by registering patents when relevant. Following expenditure of £46,000 and amortisation of £61,000, the book value of such patents and licenses was £0.22m (2019: £0.23m).
Property, plant and equipment
Expenditure of £24,000 on property, plant and equipment relates principally to £21,000 (2019: £20,000) spent on laboratory equipment to support the needs of the business. Depreciation in the year amounted to £28,000 (excluding amounts relating to Right-to-Use assets now recognised under IFRS 16) (2019: £24,000); as a result the aggregate net book value of property, plant and equipment remained broadly constant at £54,000 (2019: £58,000).
Inventories
Inventories comprise raw materials, work in progress and finished goods held at the Group's third-party contract manufacturers for sale to customers. Total inventory held at the year end fell from £0.42m in 2019 to £0.29m in 2020, principally as a result of the sales upturn in the last month of the year referred to above. Given the rapid turnover of inventory, write offs in the year were minimal.
Trade receivables
Trade receivables arising from product sales increased significantly to £1.22m (2019: £0.93m), largely due to the sharp upturn in sales experienced in the last month of the year in the then early stages of the coronavirus pandemic.
Trade receivables also arise for the Group where the consideration for the sale or license of IP (on a "right to use" basis) is structured as a series of fixed sums payable over several years. Usually there are sales-based royalties over and above these fixed sums; however, these are recognised in the period that they arise - the fixed sums are recognised on the transfer of the IP at their present value (as discounted at an imputed cost of funds). Amounts recognised in the year relating to such transactions amounted to £0.78m, arising from new and amended contracts with various partners both domestically and internationally, including the licence and product supply agreement with Tristel plc announced on 23 March 2020 (2019: £1.93m relating solely to the sale of certain IP to Solvay). Of the total trade receivables relating to IP transactions, £0.55m was due in one year (of which £0.30m was the result of a deferred income payment due on 31 March but received on 1 April) (2019: £0.28m) and £0.71m was due after one year (£0.18m). Of this balance, £0.32m was due to be collected within 2-5 years and £0.39m after 5 years (2019: £0.18m and £nil respectively).
The Group has stringent credit control policies and will not contract with customers who present an undue credit risk. In addition, the Group may request pro forma (i.e. advance) payments from new customers or existing customers who wish to increase the volume of business they do with the Group above a pre-agreed credit limit. As a result, the impairment charge for the year was minimal at £35,000 (including the expected credit loss provision required by IFRS 9 of £25,000) (2019: £41,000).
Trade and other payables
Trade payables fell marginally in the year from £0.84m to £0.83m whilst accruals and deferred income rose slightly from £0.31m to £0.37m. Within this figure is a reduction in accrued expenses offset by an increase in deferred income as the Group required customers to pay upfront for increased (or new) order volumes.
Other financial liabilities
Other financial liabilities in 2019 comprised amounts recognised in regard to contingent payments potentially due in respect of the Medimark Acquisition. As a result of the renegotiation referred to above, these were eliminated and hence the balance at 31 March 2020 was nil.
Statement of Cash Flows
Cash flow and financing
Operating cash outflow for the year was £0.46m (2019: £0.33m inflow), albeit that £0.3m of this difference was due to a single payment relating to an IP sale which was received one day after the year end and thus appeared in working capital. Expenditure capitalised as development of intangible assets was broadly consistent with the previous year (2020: £0.30m; 2019 £0.28m), as was expenditure on tangible assets (2020: £24,000; 2019 £23,000). As detailed further in Note 7, the renegotiation and resulting acceleration of the payments due to the vendors of Medimark resulted in a cash outflow of £0.29m in final settlement of the obligations resulting from this acquisition. As a result of these cash flows, gross cash fell from £2.80m at the end of 2019 to £1.71m at the end of 2020 (£2.01m as adjusted on a pro forma basis for the payment referenced above). The Group continued to make use of its invoice discounting facility in the year, drawdown on which rose from £0.25m to £0.30m at the year end.
Summary
The Group finished the year in sound financial health, with no further liabilities due in respect of the Medimark acquisition and with only modest debt. Our continuing investment in intellectual property, enhanced by the trading relationships acquired as part of the Medimark acquisition, positioned us well for the considerable upturn in demand at the very end of the year which has continued to date with a corresponding strengthening of our financial position.
Nic Hellyer
Chief Financial Officer
Group Statement of Comprehensive Income
For the year ended 31 March 2020
2020
2019
Note
£'000
£'000
(unaudited)
(audited)
Revenue
5
6,069
5,660
Cost of sales
(3,179)
(2,055)
_______
_______
Gross profit
2,890
3,605
Adjusted administrative expenses
6, 8
(2,920)
(3,018)
_______
_______
Adjusted operating profit/(loss)
(30)
587
Exceptional items
7
382
-
Amortisation of acquisition-related intangibles
(279)
(147)
Share-based payments
12
(47)
(60)
_______
_______
Operating profit
26
380
Finance income
13
59
41
Finance expense
14
(128)
(80)
_______
_______
Profit/(loss) before taxation
(43)
341
Income tax credit
15
377
11
_______
_______
Profit for the year
334
352
Other comprehensive income/(expense):
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translation of foreign operations
7
7
_______
_______
Other comprehensive income, net of tax
7
7
Total comprehensive income for the year
341
359
Earnings per share
Attributable to the owners of the Byotrol Group (basic)
16
0.08p
0.08p
Attributable to the owners of the Byotrol Group (diluted)
16
0.08p
0.08p
Group Statement of Financial Position
For the year ended 31 March 2020
2020
2019
Note
£'000
£'000
(unaudited)
(audited)
Assets
Non-current assets
Intangible assets
19
3,691
3,862
Tangible assets
20
54
58
Right-of-use assets
21
69
-
Deferred tax assets
22
431
-
Trade receivables
24
714
176
_______
_______
4,959
4,096
Current assets
Inventories
23
285
416
Trade and other receivables
24
2,185
1,796
Cash and cash equivalents
1,712
2,797
_______
_______
4,182
5,009
TOTAL ASSETS
9,141
9,105
Liabilities
Non-current liabilities
Lease liabilities
25
31
-
Deferred tax liabilities
22
394
441
Other financial liabilities
26
-
297
_______
_______
425
738
Current liabilities
Trade and other payables
27
1,319
1,193
Short term borrowings
28
296
245
Lease liabilities
25
39
-
Other financial liabilities
26
-
520
_______
_______
1,654
1,958
TOTAL LIABILITIES
2,079
2,696
NET ASSETS
7,062
6,409
Issued share capital and reserves
Share capital
29
1,101
1,077
Share premium
29
28,423
28,282
Other reserves
29
1,065
1,065
Retained earnings
(23,527)
(24,015)
_______
_______
TOTAL EQUITY
7,062
6,409
Group Statement of Cash Flows
For the year ended 31 March 2020
2020
2019
£'000
£'000
(unaudited)
(audited)
Cash flows from operating activities
Profit for the year
334
352
Adjustments for:
Finance income
(59)
(41)
Finance costs
128
80
Depreciation of tangible non-current assets
28
24
Amortisation and impairment of intangible non-current assets
467
538
Income tax (credit) recognised in profit or loss
(377)
(11)
Fair value adjustment on contingent consideration
(363)
-
Share-based payments
47
60
_______
_______
Operating cash flows before movements in working capital
205
1,002
(Increase)/decrease in trade and other receivables
(995)
(841)
(Increase)/decrease in inventories
131
(70)
Increase/(decrease) in trade and other payables
202
239
_______
_______
Cash generated from operating activities
(457)
330
Income tax paid
-
-
_______
_______
Net cash generated from operating activities
(457)
330
Cash flows from investing activities
Development of intangible assets
(295)
(283)
Acquisition of property, plant and equipment
(24)
(23)
Cash outflow on acquisition of businesses net of cash acquired
(290)
(1,131)
_______
_______
Net cash used in investing activities
(609)
(1,437)
Cash flows from financing activities
Movement in invoice discounting facility
51
16
Repayments of principal on lease liabilities
(39)
-
Finance income
6
41
Finance costs
(42)
(13)
Interest expense on lease liabilities
(3)
-
_______
_______
Net cash generated by/(used in) financing activities
(27)
44
Net increase/(decrease) in cash and cash equivalents
(1,093)
(1,063)
Foreign exchange differences
8
7
Cash and equivalent at beginning of period
2,797
3,853
_______
_______
Cash and cash equivalents at end of period
1,712
2,797
Group Statement of Changes in Equity
For the year ended 31 March 2020
Share capital
Share premium
Merger reserve
Retained earnings
Total
£'000
£'000
£'000
£'000
£'000
Balance at 1 April 2018
1,007
27,468
1,065
(24,434)
5,106
Profit after taxation for the period
-
-
-
352
352
Share-based payments
-
-
-
60
60
Other comprehensive income:
Exchange differences
-
-
-
7
7
Transactions with owners:
Shares issued by Byotrol Plc as part of a business combination
70
814
-
-
884
_____
_____
_____
_____
_____
Balance at 31 March 2019
1,077
28,282
1,065
(24,015)
6,409
Effect of change of accounting policy (IFRS 16)
-
-
-
(1)
(1)
_____
_____
_____
_____
_____
Balance at 1 April 2019 as restated
1,077
28,282
1,065
(24,016)
6,408
Profit after taxation for the period
-
-
-
334
334
Share-based payments
-
-
-
47
47
Other comprehensive income:
Deferred tax on share-based payment transactions
-
-
-
101
101
Exchange differences
-
-
-
7
7
Transactions with owners:
Shares issued by Byotrol Plc as part of a business combination
24
141
-
-
165
_____
_____
_____
_____
_____
Balance at 31 March 2020
1,101
28,423
1,065
(23,527)
7,062
Notes to the Financial Statements
As at 31 March 2020
As this summary announcement is extracted from the full financial statements, certain references may refer to notes which are not included herein, and the Notes section is not reproduced in full.
5 Revenue and segmental analysis
An analysis of revenue (and the related gross profit) by product or service and by geography is given below.
Revenue by type
To 31 March 2020
Professional
Consumer
Total
£'000
£'000
£'000
Product sales
4,410
882
5,292
Royalty and licensing income
777
-
777
_______
_______
_______
Total revenue
5,187
882
6,069
To 31 March 2019
Professional
Consumer
Total
£'000
£'000
£'000
Product sales
2,710
793
3,503
Royalty and licensing income
-
226
226
Sale of intellectual property
-
1,931
1,931
_______
_______
_______
Total revenue
2,710
2,950
5,660
Gross profit
To 31 March 2020
Professional
Consumer
Total
£'000
£'000
£'000
Product sales
1,693
420
2,113
Royalty and licensing income
777
-
777
Sale of intellectual property
-
-
-
_______
_______
_______
Total gross profit
2,470
420
2,890
To 31 March 2019
Professional
Consumer
Total
£'000
£'000
£'000
Product sales
1,093
355
1,448
Royalty and licensing income
-
226
226
Sale of intellectual property
-
1,931
1,931
_______
_______
_______
Total gross profit
1,093
2,512
3,605
Revenue by geography
The Group recognises revenue in three geographical regions based on the location of customers, as set out in the following table:
2020
2019
£'000
£'000
United Kingdom
5,230
2,701
North America
352
2,025
Rest of World
487
934
_______
_______
6,069
5,660
Management makes no allocation of costs, assets or liabilities between these segments since all trading activities are operated as a single business unit.
Customer concentration
The Group has no customers representing individually over 10% of revenue each (2019: nil).
License revenue and finance income
License contracts (and certain other contracts relating to the sale of IP) typically provide for fixed payments to be made by customers over a given term (typically between three and five years but which may extend longer). Under IFRS 15, in order to reflect the time value of money, such contracts are recognised as the capitalised value of the income stream plus notional interest accruing for the year on the credit deemed to be extended to the customer (on a reducing balance basis). For the financial year 2020 this figure amounts to license revenue of £0.78m and related notional interest income of £33,000 (2019: 1.93m and £20,000).
6 Operating expenses
Profit for the year has been arrived at after charging/(crediting):
2020
2019
£'000
£'000
Amortisation and impairment of intangible non-current assets
466
538
Depreciation of tangible non-current assets
28
24
Auditor's remuneration
30
56
Staff costs (see note 10)
1,587
1,440
Research & development costs
405
436
Research and development (R & D) tax credits
(120)
(124)
Short-term lease expenses
90
82
Realised foreign exchange (gains)/losses
(7)
1
Financial effect of initial application of IFRS 16
The tables below show the amount of adjustment for each financial statement line item affected by the application of IFRS 16 for the current period. The Group has adopted the modified retrospective approach to the application of IFRS 16 and accordingly the prior year is not restated and hence there is no effect shown.
Impact on profit/(loss) for the period
Year to 31 March 2020
£'000
(Increase) in depreciation
(39)
(Increase) in finance costs
(3)
Decrease in administrative expenses
42
_______
Effect on profit for the period
-
Impact on earnings per share for the period
There is no effect on EPS (to the nearest 0.01p).
Impact on consolidated statement of cash flows
The application of IFRS 16 has an impact on the consolidated statement of cash flows of the Group as under the Standard lessees must present:
• Short-term lease payments, payments for leases of low-value assets and variable lease payments not included in the measurement of the lease liability as part of operating activities (such payments have no material effect on these financial statements);
• Cash paid for the interest portion of lease liabilities as part of financing activities; and
• Cash payments for the repayment of the principal portions of leases liabilities as part of financing activities.
Under IAS 17, all lease payments on operating leases were presented as part of cash flows from operating activities. Consequently, for the year ended 31 March 2020, the net cash generated by operating activities has increased by £42,000 and net cash used in financing activities increased by the same amount.
For lease liabilities on the balance sheet at 31 March 2020 the Group has used a weighted average interest rate of 3.3%.
7 Exceptional items
Exceptional items of £0.38m in 2020 (2019: £57,000) comprise the gain on the adjustment of liabilities relating to contingent consideration, i.e. the potential earnout payment in respect of the acquisition of Medimark Scientific Limited ("Medimark", the "Acquisition"), less certain other costs related to the Acquisition.
Medimark was acquired pursuant to a sale and purchase agreement ("SPA") dated 22 August 2018. Consideration of up to £4.5m was payable in respect of the Acquisition, including up to £1.8m of consideration which was payable, partly in cash and partly by the issue of new ordinary shares, contingent on the achievement of certain stretch EBITDA targets in the two years following the Acquisition. Following the completion of the measurement period at 31 March 2019 the contingent consideration potentially due for the earnout years 2019 and 2020 was valued at £817,000 (as discounted to the then present value at an imputed cost of funds). This was based on a probability-weighted analysis of the potential outturns for Medimark's EBITDA for the relevant years which determined the amount payable, based on the Board's expectations at that time of the future trading performance of Medimark and how this would be accounted for as EBITDA under the terms of the SPA. At 30 September 2019 the value of this liability was revised downwards to £752,000, a £65,000 decrease (net of the unwinding of the present value discount).
On 29 January 2020, the Group completed negotiations with the four individuals who were the vendors of Medimark and agreed a payment of approximately £290,000 in cash and the issue of 9,363,034 new Ordinary shares in the Company in full and final settlement of the potential amounts outstanding under the terms of the SPA. This reduced the aggregate payments recognised in respect of the Acquisition to approximately £2.76m. Accordingly a gain of £0.44m arose based on the elimination of the contingent liability after taking into account the cost of unwinding the discount to that date. This exceptional gain has arisen through the issue of equity as well as the payment of cash; however, it is not practical to ascribe separate values to each component of the gain.
8 Non-GAAP profit measures
Reconciliation of operating profit to adjusted earnings before interest, taxation, depreciation and amortisation:
Year to 31 March
2020
2019
£'000
£'000
Operating profit
26
380
Adjusted for:
Amortisation and depreciation
534
562
Revenue recognised as interest under IFRS 15
33
20
Exceptional items:
- acquisition expenses
-
118
- gain on adjustment of contingent liability
(443)
-
- audit expenses relating to 2019
61
(61)
Total exceptional items
(382)
57
Expensed share-based payments
47
60
_______
_______
Adjusted EBITDA
258
1,079
The criteria for adjusting operating income or expenses in the calculation of adjusted EBITDA are that they are material and either (i) arise from an irregular and significant event or (ii) are such that the income/cost is recognised in a pattern that is unrelated to the resulting operational performance. Materiality is defined as an amount which, to a user, would influence decision-making based on, and understandability of, the financial statements.
Exceptional items are treated as exceptional by reason of their nature and are excluded from the calculation of adjusted EBITDA (and adjusted earnings per share in Note 16) to allow a better understanding of comparable year-on-year trading and thereby an assessment of the underlying trends in the Group's financial performance. These measures also provide consistency with the Group's internal management reporting. Exceptional items in 2020 comprise the gain on the adjustment of contingent liabilities relating to the potential earnout payment in respect of the Medimark Acquisition, plus certain accountancy and audit work which was necessary to negotiate and implement the renegotiation and final settlement (see Note 7).
Adjustment for share-based payment expense is made because, once the cost has been calculated for a given grant of options, the Directors cannot influence the share-based payment charge incurred in subsequent years relating to that grant; also the value of the share option to the employee differs considerably in value and timing from the actual cash cost to the Group.
10 Staff costs
Year to 31 March
2020
2019
£'000
£'000
Wages and salaries
1,544
1,346
Social security contributions
184
153
Other pension costs
51
34
Less: amounts capitalised as intangible assets
(192)
(93)
_______
_______
1,587
1,440
The average number of persons employed by the Company during the period was:
Year to 31 March
2020
2019
Directors
3
2
Research and development
9
7
Sales
10
12
Administration
11
7
_______
_______
33
28
11 Directors' remuneration and transactions
The Directors' emoluments in the year ended 31 March 2020 were:
Basic salary or fee
Benefits in kind
Total
Total
2020
2020
2020
2019
£'000
£'000
£'000
£'000
Executive Directors
T. Francis
83
-
83
99
N. Hellyer
55
5
60
-
D. Traynor
132
3
135
134
Non-Executive Directors
S. Gogarty
31
-
31
6
J. Langlands
40
-
40
40
T. Medinger
24
-
24
24
_______
______
_______
_______
365
8
373
303
Nic Hellyer was appointed to the board on 28 May 2019.
The remuneration of the executive Directors is decided by the Remuneration Committee. Included in the above, Sean Gogarty carried out consultancy work for the Group for which he received fees of £5,667. Save as disclosed, no Director had a material interest in any contract of significance with the Group in either year.
12 Share-based payments
The Company has granted equity-settled share options to certain directors and employees. Exercise prices of options granted are set to be equal to or more than the market value of the shares at the date of grant. Option granted have a life of 10 years.
Options outstanding
At 31 March 2020 there were options outstanding over 36,939,500 (2019: 41,448,250) ordinary shares of 0.25p each which are exercisable at prices in the range from 2.0p to 17.5p under the Company's various share option schemes, at various times until 21 July 2025. Options outstanding at 31 March 2020 had a weighted average exercise price of 3.70p (2019: 4.90p) and a weighted average remaining contractual life of 3.7 years (2019: 4.1 years).
Movements in the number of share options outstanding and their related weighted average exercise prices are as follows:
No. of options
Average exercise price
2020
2019
2020
2019
Outstanding at the beginning of the year
41,448,250
39,339,250
4.90p
5.19p
Granted during the year
4,000,000
5,000,000
2.00p
2.04p
Forfeited/cancelled during the year
(8,508,750)
(2,891,000)
8.90p
3.77p
Exchanged for shares
-
-
-
-
_______
_______
Outstanding at the end of the year
36,939,500
41,448,250
3.70p
4.90p
Options outstanding at the end of the year have a weighted average remaining contractual life of 3.7 years.
The exercise prices of options outstanding fall in the following ranges:
Range
Number of options
2.0 - 3.0p
9,000,000
3.1 - 4.0p
18,909,500
4.1 - 5.0p
7,470,000
6.0 - 7.0p
1,260,000
17.5p
300,000
_______
36,939,500
Options issued during the year
The fair values of share options issued in the year was derived using a Black Scholes model. The following key assumptions were used in the calculations:
Scheme
EMI Scheme 21 January 2020
Executive Scheme 15 May 2019
Exercise price
2.00p
2.10p
Share price at grant date
1.63p
2.65p
Risk free rate
0.39 - 0.50%
0.73 - 0.77%
Volatility
60%
55%
Expected life
1.5 - 4.5 years
3.2 - 5.2years
Fair Value
0.47 - 0.66p
1.15 - 1.27p
The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations. The number of options exercisable at 31 March 2020 is 14,933,725 (2019: 7,200,000).
The Group recognised the following expense related to share based payments:
2020
2019
£'000
£'000
Charged to Consolidated Statement of Comprehensive Income
47
60
Of this amount, £21,000 (2019: £48,000) relates to costs of share options issued to subsidiary employees.
The share price per share at 31 March 2020 was 5.43p (31 March 2019: 2.40p).
13 Finance income
2020
2019
£'000
£'000
Interest receivable on interest-bearing deposits
26
21
Notional interest accruing on contracts with a significant financing component
33
20
_______
_______
Total finance income
59
41
14 Finance expense
2020
2019
£'000
£'000
Interest and finance charges paid or payable on borrowings
45
13
Interest on lease liabilities under IFRS 16
3
-
Acquisition-related financing expense (unwinding of discount on financial liabilities)
80
67
_______
_______
Total finance expense
128
80
15 Taxation
Tax on profit on ordinary activities
Year to 31 March
2020
2019
£'000
£'000
Current tax
UK corporation tax charge/(credit) on profit for the current year
-
13
UK corporation tax charge/(credit) on Other Comprehensive Income
-
-
_______
_______
Total current income tax
-
13
Deferred tax
(Recognition) of deferred tax asset arising from temporary differences
(330)
-
(Reversal) of deferred tax liability
(47)
(24)
_______
_______
Total deferred income tax
(377)
(24)
Total income tax expense/(credit) recognised in the year
(377)
(11)
16 Earnings
Reported earnings per share
Basic earnings per share ("EPS") amounts are calculated by dividing net profit or loss for the year attributable to owners of the Company by the weighted average number of ordinary shares outstanding during the year.
The following sets out the earnings and share data used in the basic and diluted earnings per share computations:
Year to 31 March
2020
2019
£'000
£'000
Profit attributable to equity holders of the parent:
Profit attributable to ordinary equity holders of the parent for basic earnings
334
352
Weighted number of ordinary shares in issue
432,424,400
419,742,597
Effect of dilutive potential ordinary shares
703,183
191,327
_______
_______
433,127,583
419,933,924
Earnings per share attributable to shareholders - basic
0.08p
0.08p
Earnings per share attributable to shareholders - diluted
0.08p
0.08p
The Group has one category of security potentially dilutive to ordinary shares in issue, being those share options granted to employees where the exercise price (plus the remaining expected charge to profit under IFRS 2) is less than the average price of the Company's ordinary shares during the period in issue. The weighted average number of shares for the calculation of diluted earnings per share is computed using the treasury share method.
Adjusted earnings per share
Adjusted earnings per share is calculated as follows:
2020
2019
£'000
£'000
Profit attributable to ordinary equity holders of the parent for basic earnings
334
352
Adjusting items:
- exceptional items (see note 7)
(382)
57
- share-based payments
47
60
- finance expense on liabilities relating to contingent consideration
80
67
- amortisation of acquisition-related intangibles
243
147
- deferred tax credit arising from acquisition-related intangibles
(47)
(24)
_______
_______
Adjusted earnings attributable to owners of the Parent
275
659
Weighted number of ordinary shares in issue
- basic
432,424,400
419,742,597
- diluted
433,127,583
419,933,924
Adjusted earnings per share attributable to shareholders
- basic
0.06p
0.16p
- diluted
0.06p
0.16p
The criteria for inclusion of adjusting items in the calculation of adjusted EPS are the same as those relating to the calculation of adjusted EBITDA as set out in Note 8. Additionally, finance expense on liabilities relating to contingent consideration are non-cash costs reflecting the time value of money in arriving at the fair value of such liabilities and the effluxion of time over the period for which they are outstanding. Amortisation of acquisition-related intangibles (and the associated tax credit) relates to the amortisation of intangible assets in respect of customer relationships and brands which are recognised on a business combination and are non-cash in nature.
An adjustment has been made to the reported 31 March 2019 weighted average number of shares in issue (basic and diluted) to correct an error in the underlying calculation. Net assets and profits are unaffected by this adjustment.
19 Intangible assets
Intangible assets comprise capitalised development costs (in relation to internally generated technology, products and processes and those acquired through business combinations), acquired customer relationships, acquired brands, patents and licenses, and goodwill.
An analysis of goodwill and other intangible assets is as follows:
Year to 31 March 2020
Development costs
Patents and licenses
Customer relationships
Brands
Framework access rights
Goodwill
Total
£'000
£'000
£'000
£'000
£'000
£'000
£'000
Cost
At 1 April 2019
958
734
1,861
567
114
502
4,736
Additions
249
46
-
-
-
-
295
_______
_______
_______
_______
_______
_______
_______
At 31 March 2020
1,207
780
1,861
567
114
502
5,031
Amortisation and impairment
At 1 April 2019
(109)
(504)
(113)
(34)
(114)
-
(874)
Amortisation charge
(119)
(61)
(186)
(57)
-
-
(423)
Impairment charge
(43)
-
-
-
-
-
(43)
_______
_______
_______
_______
_______
_______
_______
At 31 March 2020
(271)
(565)
(299)
(91)
(114)
-
(1,340)
Net carrying amount
At 31 March 2020
936
215
1,562
476
-
502
3,691
At 1 April 2019
849
230
1,748
533
-
502
3,862
Year to 31 March 2019
Development costs
Patents and licenses
Customer relationships
Brands
Framework access rights
Goodwill
Total
£'000
£'000
£'000
£'000
£'000
£'000
£'000
Cost
At 1 April 2018
378
826
-
-
114
-
1,318
Additions
226
57
-
-
-
-
283
Created as a result of a business combination
-
-
-
-
-
502
502
Acquired as part of a business combination
501
-
1,861
567
-
-
2,929
Disposal
(147)
(149)
-
-
-
-
(296)
_______
_______
_______
_______
_______
_______
_______
At 31 March 2019
958
734
1,861
567
114
502
4,736
Amortisation or impairment
At 1 April 2018
(79)
(497)
-
-
(56)
-
(632)
Charge for the year
(177)
(156)
(113)
(34)
(58)
-
(538)
Disposal
147
149
-
-
296
_______
_______
_______
_______
_______
_______
_______
At 31 March 2019
(109)
(504)
(113)
(34)
(114)
-
(874)
Net carrying amount
At 31 March 2019
849
230
1,748
533
-
502
3,862
At 1 April 2018
299
329
-
-
58
-
686
20 Tangible assets
Year to 31 March 2020
Computer equipment
Plant and machinery
Total
£'000
£'000
£'000
Cost
At 1 April 2019
69
114
183
Additions
3
21
24
_______
_______
_______
At 31 March 2020
72
135
207
Depreciation
At 1 April 2020
(44)
(81)
(125)
Charge for the year
(16)
(12)
(28)
_______
_______
_______
At 31 March 2020
(60)
(93)
(153)
Net carrying amount
At 31 March 2020
12
42
54
At 1 April 2019
25
33
58
Year to 31 March 2019
Computer equipment
Plant and machinery
Total
£'000
£'000
£'000
Cost
At 1 April 2018
52
94
146
Additions
3
20
23
Acquired as part of a business combination
14
-
14
_______
_______
_______
At 31 March 2019
69
114
183
Depreciation
At 1 April 2018
(28)
(73)
(101)
Charge for the year
(16)
(8)
(24)
_______
_______
_______
At 31 March 2019
(44)
(81)
(125)
Net carrying amount
At 31 March 2019
25
33
58
At 1 April 2018
27
3
30
21 Right-of-use assets
The Group has adopted IFRS 16 in the year. On transition to IFRS 16, the Group recognised an additional £108,000 of right-to-use assets and £109,000 of lease liabilities, recognising the difference in retained earnings as follows (the corresponding impact on profit and loss is set out in Note 6):
As at 31 March 2019
IFRS 16 adjustments
As at 1 April 2019
£'000
£'000
£'000
Right-of-use assets
-
108
108
_______
_______
_______
Net impact on total assets
-
108
108
Lease liabilities
-
(109)
(109)
___________
_______
_______
Net impact on total liabilities
-
(109)
(109)
Retained earnings
-
1
1
_______
_______
_______
Net impact on total liabilities and equity
-
(108)
(108)
Right-of-use assets comprise leases over office buildings and vehicles as follows:
Office buildings
Vehicles
Total
£'000
£'000
£'000
Cost
At 1 April 2019
-
-
-
Effect of change of accounting policy (IFRS 16)
103
47
150
Additions in the period
-
-
-
_______
_______
_______
At 31 March 2020
103
47
150
Depreciation
At 1 April 2019
-
-
-
Effect of change of accounting policy
(29)
(13)
(42)
Charge for the period
(23)
(16)
(39)
_______
_______
_______
At 31 March 2020
(52)
(29)
(81)
Net carrying amount
At 31 March 2020
51
18
69
At 1 April 2019
-
-
-
22 Deferred tax
The following are the major deferred tax liabilities and assets recognised by the Group and movements thereon during the current and prior reporting period:
Recognised deferred tax assets
Business combinations
Tax losses
Share-based payments
Total
£'000
£'000
£'000
£'000
At 1 April 2018
-
-
-
-
Recognised on business combinations
13
13
Recognised in profit or loss
-
-
-
-
Recognised in other comprehensive income
-
-
-
-
Recognised directly in equity
-
-
-
-
Utilised against current tax charge
(13)
-
-
(13)
_______
_______
_______
_______
At 31 March 2019
-
-
-
-
At 1 April 2019
-
-
-
-
Recognised on business combinations
-
-
Recognised in profit or loss
-
330
-
330
Recognised in other comprehensive income
-
-
-
-
Recognised directly in equity
-
-
101
101
Utilised against current tax charge
-
-
-
-
_______
_______
_______
_______
At 31 March 2020
-
330
101
431
Deferred income tax assets have only been recognised to the extent that it is considered probable that they can be recovered against future taxable profits based on profit forecasts for the foreseeable future. The deferred income tax assets at 31 March 2020 above are expected to be utilised in less than one year.
At 31 March 2020 the Group had an unrecognised deferred tax asset relating to unutilised trading losses and other temporary differences of £3.57m (2019: £3.26m).
Deferred tax liabilities
2020
2019
£'000
£'000
At 1 April
441
-
Recognised on business combinations
-
465
Recognised in profit or loss
(47)
(24)
_______
_______
At 31 March
394
441
Comprising:
Amounts recognised on intangible assets arising on consolidation
394
441
_______
_______
394
441
23 Inventories
2020
2019
£'000
£'000
Raw materials and consumables
71
22
Finished goods and goods for resale
214
394
_______
_______
285
416
Included above are inventories of £nil (2019: £nil) carried at net realisable value. Inventories recognised as an expense during the year ended 31 March 2020 amounted to £2.41m (2019: £1.72m). These are included in cost of sales in the Consolidated Statement of Comprehensive Income.
Write-downs of inventories to net realisable value amounted to £13,000 (2019: £7,000). These were recognised as an expense during the year ended 31 March 2020 and included in cost of sales in the Consolidated Statement of Comprehensive Income. No earlier write downs were reversed during the current or preceding period.
24 Trade and other receivables
At 31 March
2020
2019
£'000
£'000
Trade receivables - product sales
1,223
932
Prepayments
264
273
Other receivables
132
293
Other tax repayable
19
23
Current portion of long-term trade receivables (IP sales)
547
275
_______
_______
Total other assets
2,185
1,796
Aged analysis of trade receivables
At 31 March 2020
Current
0-30 days
31-60 days
61-90 days
91-120 days
Over 120 days
Total
£'000
£'000
£'000
£'000
£'000
£'000
£'000
Gross
953
207
8
25
-
65
1,258
Specific impairment
-
-
-
-
-
(10)
(10)
Additional expected credit loss provision
(7)
(2)
(1)
(2)
-
(13)
(25)
_______
_______
_______
_______
_______
_______
_______
946
205
7
23
-
42
1,223
Non-current trade receivables
Non-current trade receivables arise most typically for the Group in sales or licenses of IP and/or know-how where the consideration is structured as a series of fixed payments (i.e. "minimum guaranteed amounts"; in addition to such payments there are usually royalty or similar payments due relating to some measure of (for example) sales made by the purchaser of the IP using the relevant products and/or in the relevant geography). Such payments may extend over several years. Under IFRS 15, if the contract is a "right to use" contract, then the upfront and fixed payments are recognised on transfer of the license or IP at their aggregate present value using an imputed cost of funds. Longer term contracts which give rise to such assets may contain continuing obligations on the part of Byotrol (for example, to provide updates or improvements to the IP transferred to the extent achieved) but such obligations are typically immaterial to the contract overall.
Current portion of long-term trade receivables
2020
2019
£'000
£'000
At 1 April
275
-
Recognised in the period, net of cash received
96
275
Transfer from non-current trade receivables
176
-
_______
_______
At 31 March
547
275
Due after one year
2020
2019
£'000
£'000
At 1 April
176
-
Recognised in the period
714
176
Transfer to current
(176)
-
_______
_______
A 31 March
714
176
No impairments have been made in respect of long-term trade receivables recognised as at the balance sheet date.
The Directors have reconsidered the presentation of certain assets shown as contract assets in the financial statements for the year ended 31 March 2019 and have concluded that they are better presented as trade receivables; accordingly these assets (amounting to £0.18m non-current and £0.27m current assets) have been represented as trade receivables above.
25 Lease liabilities
Lease liabilities comprise liabilities arising from the committed and expected payments on leases over office buildings and vehicles.
Amounts due in less than one year
Office buildings
Vehicles
Total
£'000
£'000
£'000
At 1 April 2019
-
-
-
Effect of change of accounting policy
23
16
39
Leases taken on in the period
-
-
-
Repayments of principal
(23)
(16)
(39)
Transfer from long-term to short-term
24
15
39
_______
_______
_______
At 31 March 2020
24
15
39
Amounts due in more than one year
Office buildings
Vehicles
Total
£'000
£'000
£'000
At 1 April 2019
-
-
-
Effect of change of accounting policy
53
17
70
Leases taken on in the period
-
-
-
Transfer from long-term to short-term
(24)
(15)
(39)
_______
_______
_______
At 31 March 2020
29
2
31
26 Other financial liabilities
As at 31 March
2020
2019
£'000
£'000
Contingent consideration relating to the Medimark Acquisition
- potentially due within one year
-
520
- potentially due after one year
-
297
_______
_______
-
817
The contingent consideration potentially due to the vendors of Medimark was settled on 28 January 2020 (see Note 7).
27 Trade and other payables
At 31 March
2020
2019
£'000
£'000
Due within a year
Trade payables
828
842
Social security and other taxes
119
45
Accruals and deferred income
372
306
_______
_______
Total trade and other payables
1,319
1,193
The average credit period taken for trade purchases is between 30 and 60 days. Most suppliers do not charge interest on trade payables for the first 30 days from the date of the invoice. The Group has risk management policies in place to ensure that all payables are paid within the appropriate credit time frame. The Directors consider that the carrying amount of trade payables approximates to their fair value.
Accruals comprise around £0.16m of accrued expenses plus £0.21m of customer payments received in advance.
28 Loans and borrowings
Loans and borrowings comprise:
At 31 March
2020
2019
£'000
£'000
Current liabilities
Invoice discounting facility
296
245
_______
_______
296
245
29 Share capital and reserves
Share capital and share premium
Share capital represents the nominal value of ordinary shares issued and fully paid. Share premium represents the excess of funds raised from the placing of equity shares over the nominal value of the shares after deducting directly attributable placing costs.
Ordinary shares of 0.25p each (issued and fully paid)
£'000
Number
At 1 April 2018
1,007
402,836,471
Issued as consideration for business combination during the year
70
28,048,800
_______
_______
At 31 March 2019
1,077
430,885,271
Issued as consideration for business combination during the year
24
9,363,034
_______
_______
At 31 March 2020
1,101
440,248,305
32 Capital commitments and contingent liabilities
Other than as disclosed above, as at 31 March 2020 the Group had no material capital commitments (2019: nil) nor any contingent liabilities (2019: nil).
33 Events after the reporting date
There have been no events subsequent to the reporting date which would have a material impact on the financial statements.
General
Audited accounts
The financial information set out above does not comprise the Group or the Company's statutory accounts. The Annual Report and Financial Statements for the year ended 31 March 2019 have been filed with the Registrar of Companies. The Independent Auditors' Report on the Annual Report and Financial Statements ("Annual Report") for the year ended 31 March 2019 was qualified by reference to the auditor's inability to perform all their planned audit procedures with regard to certain bank accounts for which they could not obtain satisfactory third party confirmation, but otherwise did not draw attention to any matters by way of emphasis, and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.
The audit for the year ended 31 March 2020 has yet to be completed and audited accounts will be published in due course.
Related party transactions
Other than as disclosed above, no related party transactions have taken place during the year that have materially affected the financial position or performance of the Company or the Group.
Principal risks and uncertainties
The principal risks and uncertainties facing the Group together with actions being taken to mitigate them and future potential items for consideration will be set out in the Strategic Report section of the Annual Report and Financial Statements for 2020.
Presentation of figures
Figures are rounded to the nearest £0.1m, £0.01m or £'000 (or in the case of EPS, nearest 0.01p) as the case may be. Percentage increases or decreases stated above are based on the figures as rounded. Minor differences may arise in tabulation and figures presented elsewhere due to rounding differences.
This announcement was approved by the Board of Directors on 23 September 2020.
[END]
[1] i.e. earnings before interest, tax, depreciation, amortisation and exceptional and other adjusting items - see Note 8
[2] i.e. gross cash less financial debt
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FR LJMPTMTTTBTM
